Tags

Type your tag names separated by a space and hit enter

[Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
Schweiz Med Wochenschr. 1990 Mar 03; 120(9):295-8.SM

Abstract

Hyperphosphatemia in chronic hemodialysis patients is usually treated with aluminium containing phosphate binders. In recent years there has been increasing evidence of serious complications due to aluminium accumulation. We have investigated a new calcium carbonate preparation with an HCl-resistant capsule designed to prevent gastrointestinal side effects. Its phosphate binding capacity in comparison to aluminium chloride hydroxide was investigated in 17 chronic hemodialysis patients. The dose of the phosphate binder was adjusted regularly so that the serum phosphorus levels were below 1.8 mmol/l. The mean dose of aluminium chloride hydroxide was 3.36 g/day and of calcium carbonate 4.96 g/day. The mean (+/- SD) serum calcium level was 2.58 +/- 0.11 mmol/l under aluminium chloride hydroxide and 2.50 +/- 0.25 mmol/l under calcium carbonate. The mean phosphorus level was 1.69 +/- 0.31 mmol/l under aluminium chloride hydroxide and 1.71 +/- 0.33 under calcium carbonate. Serum aluminium fell from 64.5 +/- 14.4 micrograms/l to 28.5 +/- 17.5 micrograms/l after 3 months.

Authors+Show Affiliations

Dialysestation der Medizinischen Klinik, Kantonsspital, Liestal.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

ger

PubMed ID

2315655

Citation

Kiss, D, et al. "[Calcium Carbonate for the Treatment of Hyperphosphatemia in Chronic Hemodialysis Patients]." Schweizerische Medizinische Wochenschrift, vol. 120, no. 9, 1990, pp. 295-8.
Kiss D, Battegay M, Meier C, et al. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients]. Schweiz Med Wochenschr. 1990;120(9):295-8.
Kiss, D., Battegay, M., Meier, C., & Lyrer, A. (1990). [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients]. Schweizerische Medizinische Wochenschrift, 120(9), 295-8.
Kiss D, et al. [Calcium Carbonate for the Treatment of Hyperphosphatemia in Chronic Hemodialysis Patients]. Schweiz Med Wochenschr. 1990 Mar 3;120(9):295-8. PubMed PMID: 2315655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients]. AU - Kiss,D, AU - Battegay,M, AU - Meier,C, AU - Lyrer,A, PY - 1990/3/3/pubmed PY - 1990/3/3/medline PY - 1990/3/3/entrez SP - 295 EP - 8 JF - Schweizerische medizinische Wochenschrift JO - Schweiz Med Wochenschr VL - 120 IS - 9 N2 - Hyperphosphatemia in chronic hemodialysis patients is usually treated with aluminium containing phosphate binders. In recent years there has been increasing evidence of serious complications due to aluminium accumulation. We have investigated a new calcium carbonate preparation with an HCl-resistant capsule designed to prevent gastrointestinal side effects. Its phosphate binding capacity in comparison to aluminium chloride hydroxide was investigated in 17 chronic hemodialysis patients. The dose of the phosphate binder was adjusted regularly so that the serum phosphorus levels were below 1.8 mmol/l. The mean dose of aluminium chloride hydroxide was 3.36 g/day and of calcium carbonate 4.96 g/day. The mean (+/- SD) serum calcium level was 2.58 +/- 0.11 mmol/l under aluminium chloride hydroxide and 2.50 +/- 0.25 mmol/l under calcium carbonate. The mean phosphorus level was 1.69 +/- 0.31 mmol/l under aluminium chloride hydroxide and 1.71 +/- 0.33 under calcium carbonate. Serum aluminium fell from 64.5 +/- 14.4 micrograms/l to 28.5 +/- 17.5 micrograms/l after 3 months. SN - 0036-7672 UR - https://www.unboundmedicine.com/medline/citation/2315655/[Calcium_carbonate_for_the_treatment_of_hyperphosphatemia_in_chronic_hemodialysis_patients]_ L2 - https://medlineplus.gov/dialysis.html DB - PRIME DP - Unbound Medicine ER -